AstraZeneca PLC 2025 Block Listing Interim Review Report

Here are the key takeaways from the provided section of the financial report for AstraZeneca PLC:

1. Document Type and Purpose:

• This is a Form 6-K filing, which is used by foreign companies to report to the SEC.
• The report specifically relates to a "Block Listing Interim Review" for the month of June 2025.

2. Company Information:

• Company Name: AstraZeneca PLC
• Commission File Number: 001-11960
• Headquarters: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.

3. Securities Reporting:

• The report confirms that AstraZeneca files annual reports under Form 20-F, but not under Form 40-F.
• The registrant did not submit this Form 6-K in paper form.

4. Block Listing Details:

• Name of Applicant: AstraZeneca PLC
• Name of Scheme: Multiple share option plans including AstraZeneca Share Option Plan and others.
• Period of Return: From December 1, 2024, to May 31, 2025.

5. Securities Information:

• Balance of Unallotted Securities: 4,029,156 from the previous return.
• Increase in Block Scheme: No increase applied for.
• Securities Issued/Allotted During Period: 340,773.
• Balance Not Yet Issued/Allotted at End of Period: 3,688,383.

6. Contact Information:

• Contact Name: Hannah Tattersall.
• Telephone Number: +44 (0)20 3749 5000.

7. Company Overview:

• AstraZeneca is described as a global, science-led biopharmaceutical company focusing on various therapeutic areas including Oncology, Rare Diseases, and Cardiovascular health.

8. Signature:

• The report is signed by Adrian Kemp, the Company Secretary, confirming the submission of the report.

This report provides insights into AstraZeneca's ongoing commitments to its share option plans, securities management, and compliance with SEC regulations.